Orodispersible tablets

Abstract

This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.

1 . An orally disintegrating tablet obtained by direct compression of a dry powdered mixture, said mixture comprising:
 up to 15% by weight of calcium silicate;   at least 50% by weight of a diluent, wherein said diluent is selected from the group consisting of anhydrous lactose, lactose monohydrate, agglomerated lactose, atomised forms of lactose, microcrystalline cellulose, and mixtures thereof;   at least a disintegrant; and   rizatriptan as an active ingredient,   
       wherein said orally disintegrating tablet presents a friability no greater than 1% and a disintegration time of less than 20 seconds, and wherein the dry powder mixture has not been subjected to any granulation process, dissolution, or dispersion in a liquid medium. 
     
     
         2 . The tablet according to  claim 1 , wherein the tablet's thickness is less than 30% of the tablet's major diameter. 
     
     
         3 . (canceled) 
     
     
         4 . The tablet according to  claim 1 , wherein the calcium silicate is crystalline. 
     
     
         5 . The tablet according to  claim 1 , wherein the calcium silicate is ortho-, meta- or alpha triclinic-calcium silicate. 
     
     
         6 . The tablet according to  claim 1 , wherein said calcium silicate is amorphous. 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . The tablet according to  claim 1 , wherein the disintegrant is selected from the group consisting of crospovidone, sodium croscarmellose, sodium starch glycolate, low-substituted hydroxypropyl cellulose and pregelatinized starch. 
     
     
         10 . The tablet according to  claim 10 , wherein the disintegrant is crospovidone or sodium croscarmellose. 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . The tablet according to  claim 1 , wherein the powdered mixture further comprises an effervescent component. 
     
     
         15 . A process for the preparation of a tablet as defined in  claim 1 , which comprises:
 a) mixing the dry powdered ingredients in the required amount, and   b) applying direct compression to the mixture obtained in step a),   wherein the mixture obtained in step a) has not been subjected to any granulation process, dissolution, or dispersion in a liquid medium.   
     
     
         16 . The tablet according to  claim 1 , wherein the dry powder comprises from 1 to 20% by weight of active ingredient. 
     
     
         17 . The tablet according to  claim 1 , wherein said calcium silicate, lactose diluent, at least one disintegrant, and rizatriptan have been previously and independently passed through a sieve with mesh size lower than 650 μm. 
     
     
         18 . The process of  claim 15 , wherein said calcium silicate, lactose diluent, at least one disintegrant, and rizatriptan have been previously and independently passed through a sieve with mesh size lower than 650 μm. 
     
     
         19 . The tablet according to  claim 1 , wherein the mixture comprises up to 10 weight % of calcium silicate.